AbbVie Files Fast-Acting/Shorter-Duration Botox Alternative for FDA Approval

In major news for the medspa industry, AbbVie has filed for approval of a fast-acting, short-duration Botox alternative known as TrenibotulinumtoxinE (TrenibotE). This new injectable aims to target moderate to severe frown lines with results that start showing in as little as eight hours, much faster than traditional Botox, which usually takes 3–7 days to take full effect. If approved, TrenibotE could offer a more temporary solution for clients who are hesitant about longer-lasting treatments.

What Is TrenibotE?

TrenibotE is a serotype E neurotoxin designed to address aesthetic concerns like frown lines. Unlike Botox, whose effects last three to four months, TrenibotE’s effects will last only two to three weeks. This shorter duration might be appealing to first-time clients or those looking for a less permanent commitment to aesthetic treatments.

For many, the longer duration of Botox (and its competitors) can create hesitation, particularly for those who are nervous about looking “unnatural.” With TrenibotE, those new to neurotoxin injections could experience results quickly and with fewer concerns about a long-lasting change.

Why Does This Matter for Medspas?

If approved by the FDA, TrenibotE could open up exciting new opportunities for medspa owners. The rapid onset and shorter duration make it a perfect treatment for clients looking for quick fixes before special events, such as weddings or reunions. Medspas can market this as a trial run for those considering Botox but not quite ready for a longer-lasting commitment.

The quicker results could also mean more frequent visits for touch-ups, increasing overall treatment volume and revenue potential. Additionally, the fact that TrenibotE might appeal to first-timers could help expand your customer base, especially with people who may have been previously hesitant to try Botox.

Market Competition and AbbVie’s Strategy

Botox has been a market leader in neurotoxin-based aesthetic treatments for decades. However, with increased competition from products like Dysport, Xeomin, and the new Letybo, AbbVie’s goal is to regain market share. TrenibotE, which is specifically targeted to new users, is seen as an opportunity to bring more people into the neurotoxin category and convert them into long-term Botox clients.

AbbVie is also exploring ways to combine TrenibotE with Botox to offer the best of both worlds: the fast-acting benefits of TrenibotE with the longer-lasting effects of Botox. This combination approach could be a unique selling point for medspas to market to their existing Botox clients.

The Road Ahead

AbbVie has already completed Phase 3 clinical trials, showing promising results for rapid onset and short duration. The next step is FDA approval, which could come as soon as late 2025. If successful, TrenibotE will likely be available to medspas as an option for trial treatments and quick aesthetic fixes.